These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31760494)

  • 21. Blood pressure targets for hypertension in people with diabetes mellitus.
    Arguedas JA; Leiva V; Wright JM
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD008277. PubMed ID: 24170669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease.
    Shen Y; Dai Y; Wang XQ; Zhang RY; Lu L; Ding FH; Shen WF
    Cardiovasc Diabetol; 2019 Nov; 18(1):160. PubMed ID: 31733658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2016 Apr; 34(4):613-22. PubMed ID: 26848994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
    Petrie JR; Marso SP; Bain SC; Franek E; Jacob S; Masmiquel L; Leiter LA; Haluzik M; Satman I; Omar M; Shestakova M; Van Gaal L; Mann JF; Baeres FM; Zinman B; Poulter NR;
    J Hypertens; 2016 Jun; 34(6):1140-50. PubMed ID: 26855018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial.
    Contreras G; Lu L; Tamariz L; Rocco MV; Papademetriou V; Kostis JB; Pisoni R; Glasser SP; Sweeney ME; Basile J; Gren LH; Zamanian S; Cushman WC;
    J Hypertens; 2020 Aug; 38(8):1567-1577. PubMed ID: 32371767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target Blood Pressure in Patients with Diabetes: Asian Perspective.
    Park S; Kario K; Park CG; Huang QF; Cheng HM; Hoshide S; Wang JG; Chen CH;
    Yonsei Med J; 2016 Nov; 57(6):1307-11. PubMed ID: 27593856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?
    Bhatt H; Ghazi L; Calhoun D; Oparil S
    Curr Cardiol Rep; 2016 Oct; 18(10):98. PubMed ID: 27566331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 Nov; 35(11):2138-2149. PubMed ID: 28858983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2018 Aug; 36(8):1622-1636. PubMed ID: 29847485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure treatment target in patients with diabetes mellitus--current evidence.
    Barengo NC; Tuomilehto JO
    Ann Med; 2012 Jun; 44 Suppl 1():S36-42. PubMed ID: 22713147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.
    Ó Hartaigh B; Szymonifka J; Okin PM
    J Hypertens; 2018 Jan; 36(1):101-109. PubMed ID: 28832365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.
    Chen LY; Bigger JT; Hickey KT; Chen H; Lopez-Jimenez C; Banerji MA; Evans G; Fleg JL; Papademetriou V; Thomas A; Woo V; Seaquist ER; Soliman EZ
    Am J Hypertens; 2016 Nov; 29(11):1276-1282. PubMed ID: 26476086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?
    Zanchetti A; Ruilope LM
    J Hypertens; 2002 Nov; 20(11):2099-110. PubMed ID: 12409940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment.
    Zhou J; Xu B; He F; Shu Y; Chen X; Liu Z; Sun B; Zhang W
    Cardiovasc Diabetol; 2024 May; 23(1):166. PubMed ID: 38730425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies.
    Zhang Y; Liang M; Sun C; Qu G; Shi T; Min M; Wu Y; Sun Y
    J Hum Hypertens; 2019 Sep; 33(9):648-657. PubMed ID: 31363149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers.
    Kalaitzidis R; Bakris G
    Diabetes Obes Metab; 2009 Aug; 11(8):757-69. PubMed ID: 19519867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.